Finding a Safe Dose of Rhenium-186 Treatment for Young People With Ependymoma or High-Grade Glioma
Official title: Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests how much of a new treatment young people with hard-to-treat brain tumors can safely take.
Read our full plain-language summary
What the trial team says
Pediatric patients 6-21 years of age with supratentorial recurrent, refractory, or progressive pediatric ependymoma and high-grade glioma (HGG) will be included in this study of treatment with Rhenium-186 Nanoliposome (186RNL). Phase 1 of the study will look to determine the maximum tolerated dose (MTD) of 186RNL in this patient population. Phase 2 of the study will use the recommended dose determined in Phase 1 to continue to look at overall response rate and progression-free survival following 186RNL treatment.
Key facts
- Registry number
- NCT07061626
- Stage of testing
- Phase 1
- Conditions studied
- Ependymoma, High Grade Gliomas
Where it is running
This trial lists 1 site.
-
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago (Chicago)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.